MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Actinium Pharmaceuticals Inc

Slēgts

1.72 5.52

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.69

Max

1.73

Galvenie mērījumi

By Trading Economics

Ienākumi

-9.3M

-16M

Darbinieki

31

EBITDA

-9.3M

-17M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+250.88% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 1. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

624K

49M

Iepriekšējā atvēršanas cena

-3.8

Iepriekšējā slēgšanas cena

1.72

Actinium Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 18. jūl. 21:01 UTC

Peļņas

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 18. jūl. 20:46 UTC

Peļņas

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

2025. g. 18. jūl. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025. g. 18. jūl. 20:36 UTC

Peļņas

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

2025. g. 18. jūl. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

2025. g. 18. jūl. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 18. jūl. 20:02 UTC

Tirgus saruna

Gold Higher to Close Out Week -- Market Talk

2025. g. 18. jūl. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

2025. g. 18. jūl. 19:06 UTC

Tirgus saruna

Oil Futures Snap Two-Week Winning Streak -- Market Talk

2025. g. 18. jūl. 18:24 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

2025. g. 18. jūl. 18:19 UTC

Peļņas

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

2025. g. 18. jūl. 18:11 UTC

Iegādes, apvienošanās, pārņemšana

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

2025. g. 18. jūl. 18:11 UTC

Peļņas

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

2025. g. 18. jūl. 17:35 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

2025. g. 18. jūl. 16:29 UTC

Tirgus saruna

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

2025. g. 18. jūl. 16:28 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025. g. 18. jūl. 16:22 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Energy & Utilities Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 18. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 18. jūl. 16:04 UTC

Peļņas

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

2025. g. 18. jūl. 15:58 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 18. jūl. 15:58 UTC

Tirgus saruna

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

2025. g. 18. jūl. 15:47 UTC

Tirgus saruna
Peļņas

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Salīdzinājums

Cenas izmaiņa

Actinium Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

250.88% augšup

Prognoze 12 mēnešiem

Vidējais 6 USD  250.88%

Augstākais 9 USD

Zemākais 4 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Actinium Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

3

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.